Automated Insulin Delivery Systems
Summary
An FDA-cleared or approved automated insulin delivery system with a low glucose suspend feature may be considered medically necessary for type 1 diabetes in individuals age 6 years and older with HbA1c between 5.8% and 10.0%, more than 6 months of insulin pump therapy, and at least 2 documented nocturnal hypoglycemic events in a 2-week period. A hybrid closed-loop system may be considered medically necessary for type 1 diabetes in individuals over age 6 who meet the same HbA1c and pump criteria, or in ages 2 to 6 with type 1 diabetes for 3 months or more, pump therapy for more than 3 months, HbA1c below 10.0% and a total daily dose of at least 8 units; a closed-loop system may be considered for individuals age 6 and older with type 1 diabetes for 12 months or more who have used insulin for at least 12 months. For type 2 diabetes, a hybrid closed-loop system may be considered medically necessary in individuals age 18 and older diagnosed for at least 12 months who take at least 3 insulin injections daily or use an insulin infusion pump for at least 3 months and have HbA1c of 7% or higher or significant hypoglycemia, and use for individuals who do not meet these criteria or for systems not cleared or approved by the FDA is investigational.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.